

Table S3. Participants under obstructive airway disease treatment by ATC subgroups (total vaccinated cohort)

ATC chemical-therapeutic-pharmacological subgroup, n (%)	OAD-treated adults (meta-analysis) N=222
Adrenergics, inhalants (R03A)	
Alpha- and beta-adrenoreceptor agonists (R03AA)	7 (3.2)
Non-selective beta-adrenoreceptor agonists (R03AB)	1 (0.5)
Selective beta-2-adrenoreceptor agonists (R03AC)	134 (60.4)
Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics (R03AK)	89 (40.1)
Other drugs for obstructive airway diseases, inhalants (R03B)	
Glucocorticoids (R03BA)	43 (19.4)
Anticholinergics (R03BB)	38 (17.1)
Antiallergic agents, excluding corticosteroids (R03BC)	2 (0.9)
Other drugs for obstructive airway diseases, inhalants (R03BX)	3 (1.4)
Adrenergics for systemic use (R03C)	
Non-selective beta-adrenoreceptor agonists (R03CB)	1 (0.5)
Selective beta-2-adrenoreceptor agonists (R03CC)	129 (58.1)
Adrenergics and other drugs for obstructive airway diseases (R03CK)	2 (0.9)
Other systemic drugs for obstructive airway diseases (R03D)	
Xanthines (R03DA)	3 (1.4)
Leukotriene receptor antagonists (R03DC)	19 (8.6)
Corticosteroids, plain (D07A)	
Corticosteroids, weak (group I) (D07AA)	2 (0.9)
Corticosteroids, moderately potent (group II) (D07AB)	2 (0.9)
Corticosteroids, potent (group III) (D07AC)	23 (10.4)

ATC, Anatomical Therapeutic Chemical; n, number of participants in a given category; OAD, obstructive airway disease; N, number of adults in the total vaccinated cohort.